- Anti-Nuclear Antibody (ANA) tests are critical diagnostic tools used to detect autoantibodies in the blood, aiding in the diagnosis of autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and Sjögren’s syndrome. These tests play a vital role in early detection and management of these conditions
- The growing incidence of autoimmune disorders, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis, is propelling the demand for ANA testing across the region
- China is expected to dominate the Asia-Pacific anti-nuclear antibody test market with 32.4% market share, driven by its large population base, increasing prevalence of autoimmune diseases, and significant investments in healthcare infrastructure
- India is expected to be the fastest growing country with a CAGR of 14.6% in the Asia-Pacific anti-nuclear antibody test market driven by rising healthcare awareness and increasing healthcare spending
- ELISA (Enzyme-Linked Immunosorbent Assay) is expected to dominate the market with a market share of 52.60% due to its high sensitivity, cost-effectiveness, and widespread availability, making it the preferred choice for large-scale screening in clinical laboratories
